22,800 Shares in Royalty Pharma PLC $RPRX Acquired by WINTON GROUP Ltd

WINTON GROUP Ltd bought a new position in Royalty Pharma PLC (NASDAQ:RPRX) in the second quarter, HoldingsChannel.com reports. The fund bought 22,800 shares of the biopharmaceutical company’s stock, valued at approximately $1,278,000.

A number of other hedge funds also recently bought and sold shares of the company. LM Advisors LLC purchased a new position in shares of Royalty Pharma in the fourth quarter worth approximately $26,000. Lloyd Advisory Services LLC. bought a new position in Royalty Pharma in the fourth quarter worth approximately $30,000. Blue Trust Inc. raised its position in Royalty Pharma by 173.4% in the first quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 437 shares during the period. CIBC Private Wealth Group LLC boosted its stake in shares of Royalty Pharma by 66.4% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 446 shares during the last quarter. Finally, Larson Financial Group LLC boosted its stake in shares of Royalty Pharma by 31.9% during the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 306 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Marshall Urist sold 9,099 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $55.88, for a total transaction of $508,452.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 150,000 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $54.40, for a total transaction of $8,160,000.00. Following the transaction, the executive vice president directly owned 559,399 shares of the company’s stock, valued at $30,431,305.60. The trade was a 21.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 398,197 shares of company stock valued at $22,513,280. 18.84% of the stock is owned by company insiders.

Royalty Pharma Price Performance

Shares of RPRX opened at $58.61 on Monday. The business’s 50 day moving average is $59.33 and its 200 day moving average is $53.67. The company has a market capitalization of $33.70 billion, a PE ratio of 40.42, a price-to-earnings-growth ratio of 1.38 and a beta of 0.44. Royalty Pharma PLC has a 12-month low of $34.63 and a 12-month high of $64.38. The company has a current ratio of 2.80, a quick ratio of 2.80 and a debt-to-equity ratio of 0.88.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.05. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%.The business had revenue of $674.14 million during the quarter, compared to the consensus estimate of $758.93 million. Research analysts expect that Royalty Pharma PLC will post 5.32 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, September 10th. Stockholders of record on Friday, August 14th were issued a $0.235 dividend. This represents a $0.94 annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend was Friday, August 14th. Royalty Pharma’s payout ratio is 64.83%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Wall Street Zen upgraded Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings restated a “buy (b-)” rating on shares of Royalty Pharma in a research note on Wednesday, August 12th. Morgan Stanley reaffirmed an “overweight” rating and set a $65.00 price target on shares of Royalty Pharma in a report on Thursday, August 6th. The Goldman Sachs Group reissued a “buy” rating and issued a $66.00 price objective on shares of Royalty Pharma in a research note on Thursday, August 6th. Finally, Bank of America restated a “buy” rating on shares of Royalty Pharma in a research report on Wednesday, August 5th. Eight investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $61.29.

Royalty Pharma Profile

Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to life sciences companies in exchange for rights to receive future royalty payments from commercialized or late-stage therapies. Rather than developing and marketing medicines itself, the company invests in pharmaceutical and biotechnology innovations and seeks to generate income from the resulting royalty streams.

Its portfolio is linked to a range of therapies across areas including oncology, immunology, neuroscience, rare diseases and other specialty markets.